{"id":"NCT01232894","sponsor":"Novartis Pharmaceuticals","briefTitle":"12-week Open-label Evaluation of Efficacy and Safety of Indacaterol","officialTitle":"A 12 Week, Multi-center, Randomized, Open Label Study, eValuating the Efficacy and Safety of Treatment Regimens That Include ONbrez (Indacaterol) in Patients With Moderate to Severe COPD (MOVE-ON Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2010-11-02","resultsPosted":"2013-11-19","lastUpdate":"2013-11-19"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":[]},{"type":"DRUG","name":"Long-acting beta2-agonist","otherNames":[]}],"arms":[{"label":"Indacaterol","type":"EXPERIMENTAL"},{"label":"Long-acting beta2-agonist","type":"ACTIVE_COMPARATOR"}],"summary":"In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.","primaryOutcome":{"measure":"Change From Baseline on Clinical COPD Questionnaire (CCQ) Score","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Indacaterol","deltaMin":1.8,"sd":1},{"arm":"Long-acting beta2-agonist","deltaMin":1.7,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":8,"countries":["Israel"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":59},"commonTop":["Chronic obstructive pulmonary disease","Cough","Dizziness"]}}